| Product Code: ETC6361489 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Belgium Plasma Protease C1-inhibitor Treatment Market Overview |
3.1 Belgium Country Macro Economic Indicators |
3.2 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Belgium Plasma Protease C1-inhibitor Treatment Market - Industry Life Cycle |
3.4 Belgium Plasma Protease C1-inhibitor Treatment Market - Porter's Five Forces |
3.5 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Dosage Type, 2021 & 2031F |
3.7 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Belgium Plasma Protease C1-inhibitor Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about plasma protease C1-inhibitor treatment for hereditary angioedema (HAE) |
4.2.2 Rising prevalence of HAE in Belgium |
4.2.3 Technological advancements in plasma protease C1-inhibitor treatments |
4.3 Market Restraints |
4.3.1 High cost associated with plasma protease C1-inhibitor treatments |
4.3.2 Limited availability of specialized healthcare facilities for administering the treatment |
4.3.3 Stringent regulatory requirements for plasma protease C1-inhibitor products |
5 Belgium Plasma Protease C1-inhibitor Treatment Market Trends |
6 Belgium Plasma Protease C1-inhibitor Treatment Market, By Types |
6.1 Belgium Plasma Protease C1-inhibitor Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By C1-inhibitors, 2021- 2031F |
6.1.4 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By C1-esterase Inhibitor, 2021- 2031F |
6.1.5 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Kallikrein Inhibitor (Kalbitor), 2021- 2031F |
6.1.6 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Selective Bradykinin B2 Receptor Antagonist (Firazyr), 2021- 2031F |
6.2 Belgium Plasma Protease C1-inhibitor Treatment Market, By Dosage Type |
6.2.1 Overview and Analysis |
6.2.2 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Liquid/Injectable, 2021- 2031F |
6.2.3 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Lyophilized, 2021- 2031F |
6.3 Belgium Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Belgium Plasma Protease C1-inhibitor Treatment Market Revenues & Volume, By Independent Pharmacies and Outlets, 2021- 2031F |
7 Belgium Plasma Protease C1-inhibitor Treatment Market Import-Export Trade Statistics |
7.1 Belgium Plasma Protease C1-inhibitor Treatment Market Export to Major Countries |
7.2 Belgium Plasma Protease C1-inhibitor Treatment Market Imports from Major Countries |
8 Belgium Plasma Protease C1-inhibitor Treatment Market Key Performance Indicators |
8.1 Patient adherence rate to plasma protease C1-inhibitor treatment |
8.2 Number of healthcare professionals trained in administering the treatment |
8.3 Frequency of hospitalizations for acute HAE attacks |
9 Belgium Plasma Protease C1-inhibitor Treatment Market - Opportunity Assessment |
9.1 Belgium Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Belgium Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Dosage Type, 2021 & 2031F |
9.3 Belgium Plasma Protease C1-inhibitor Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Belgium Plasma Protease C1-inhibitor Treatment Market - Competitive Landscape |
10.1 Belgium Plasma Protease C1-inhibitor Treatment Market Revenue Share, By Companies, 2024 |
10.2 Belgium Plasma Protease C1-inhibitor Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here